common.study.topics.clinical

Synaptic Density in Psychiatric Disorders

common.study.values.description

“SV2 PET Imaging With [11C]APP311”

The aim of this study is to evaluate a new SV2A tracer, [11C]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Radiation - [11C]APP311

It has been shown that [11C]APP311 (aka [11C]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311

common.study.values.clinical-trial-id

NCT03995121

participant.views.study.view.id

bo2WXa